Tagged with P

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta includes Zelgen Biopharm licensing its CD3×DLL3 TCE to AbbVie in a deal worth over US$1.2B, with milestone payments and tiered royalties. Biokin proposes RMB 10B in debt financing to fuel innovation, highlighted by its advanced ADC programs. Insilico Medicine successfully…

Taiwan Under Dave Huang’s leadership, Ferring Taiwan has evolved from organisational recovery to sustained performance and regional relevance. The discussion that follows examines how disciplined focus, early engagement with innovation, and deep collaboration with the healthcare ecosystem have reshaped the affiliate’s role, positioning Taiwan as a reference market while anchoring strategy…

Hong Kong Drawing on over two decades of leadership industry across Asia, Cecilia Qi reflects her transition from global pharma to leading DCH Auriga. She shares insights on the company’s evolution into an integrated market management partner, the strategic role of Hong Kong, and the future of healthcare distribution in Asia. Agility…

Taiwan Hung Lai Wu, Chairperson of the Taiwan Alliance of Patients’ Organisations (TAPO) and a home dialysis patient for 18 years, has transformed personal experience into systemic advocacy. Since becoming a member of the board of directors of TAPO in 2016, she has championed patient representation within Taiwan’s National Health Insurance…

France MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of acute unmet need. Hervé Affagard recounts how a personal catalyst, an engineering mindset and early scientific partnerships shaped a platform now approaching its first potential approval for its first microbiome drug candidate. The journey…

Global 2025 was a year of volatility for pharma and healthcare. In particular, the speed with which the administration of Donald Trump makes (and often then changes) consequential policy decisions has left industry stakeholders in the US and globally scrambling to fall in line. There are already clear winners and losers…

USA Michael Pearlmutter, CEO of the EveryLife Foundation for Rare Diseases (the EveryLife Foundation), brings a deeply personal motivation and commitment to driving meaningful change for the rare disease community. In this conversation, Pearlmutter reflects on the Foundation’s mission, its impact across the rare disease ecosystem, and the evolving opportunities to…

Brazil Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology transfer agreements is bolstering local manufacturing capabilities and helping these companies scale the value chain. Multinationals – with the right…

Taiwan Dr Shuling Cheng is steering Oneness Biotech through a pivotal transition from a Taiwan-based research organisation to a globally focused commercial company. After 25 years in US biotech and medtech, she returned to Taiwan a decade ago and brought two companies to IPO on the Taipei stock exchange.  She joined…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX debut, and Juncell’s Hong Kong IPO filing targeting China’s first TIL therapy. Biocytogen listed on Shanghai’s STAR Market for its…

Brazil Danielle Bibas leads Pierre Fabre’s operations in Brazil, overseeing three key dermo-cosmetic brands – Avène, Darrow, and Ducray – in the world’s third-largest beauty market. Since assuming the role in January 2025, she has focused on navigating the rapidly transforming skincare landscape, balancing traditional physician relationships with emerging digital channels,…

Taiwan PharmaEngine is entering a defining phase as it strengthens its development-only roots while expanding into early discovery, differentiated DNA damage response programmes and AI-enabled design. In this conversation, CEO Hong-Ren Wang outlines how ONIVYDE® provides the stability to advance a more ambitious pipeline, how a virtual model sharpens scientific focus…